WHO ICTRP trial
Multicenter Phase-II-Study with Capecitabine/Trastuzumab as first-line therapy…
DRKS00000600 · German Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | DRKS00000600 |
|---|---|
| Public title | Multicenter Phase-II-Study with Capecitabine/Trastuzumab as first-line therapy for advanced HER2-overexpressing pancreas carcinoma |
| Scientific title | Multicenter Phase-II-Study with Capecitabine/Trastuzumab as first-line therapy for advanced HER2-overexpressing pancreas carcinoma - ML17-743 |
| Primary sponsor | Universitätsklinikum Freiburg Abteilung Innere Medizin II - Gastroenterologie, Hepatologie, Endokrinologie und Infektiologie |
| Registry | German Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 2 |
| Countries | Germany |
| Conditions | MedDRA - 10033576 C25.9;Pancreas, unspecified;C25.9 |
| Interventions | Group 1: Trastuzumab 4 mg/kg as initial infusion, followed by 2 mg/kg weekly and Capecitabin 2 x 1250 mg/m2 daily for days 1-14 followed by 7 days pause; repeated every three weeks until tumour progression. |
| Registration date | Nov 11, 2010 |
| Target size | 37 |
| Secondary IDs | ML 17 743;UKF000577;4021536 |
| Registry page | drks.de |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: